Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $156.60.

Several research firms have issued reports on SRPT. Wedbush restated an "outperform" rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. BMO Capital Markets began coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They set an "outperform" rating and a $170.00 price objective on the stock. Citigroup boosted their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Evercore ISI boosted their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a report on Tuesday, February 20th. Finally, Royal Bank of Canada lifted their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a research note on Thursday, February 29th.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded up $1.38 during midday trading on Friday, hitting $128.77. The company's stock had a trading volume of 1,236,000 shares, compared to its average volume of 997,301. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The stock's 50-day moving average price is $126.11 and its 200-day moving average price is $110.47. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89. The company has a market capitalization of $12.09 billion, a PE ratio of -21.04 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.50. The firm had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.24) EPS. Analysts anticipate that Sarepta Therapeutics will post 2.13 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now owns 26,836 shares of the company's stock, valued at $3,457,550.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares of the company's stock, valued at $3,457,550.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Avior Wealth Management LLC raised its stake in shares of Sarepta Therapeutics by 60.8% in the third quarter. Avior Wealth Management LLC now owns 3,295 shares of the biotechnology company's stock valued at $399,000 after purchasing an additional 1,246 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Sarepta Therapeutics by 14.5% in the third quarter. Handelsbanken Fonder AB now owns 15,915 shares of the biotechnology company's stock valued at $1,929,000 after purchasing an additional 2,013 shares in the last quarter. Peregrine Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 12.9% in the third quarter. Peregrine Capital Management LLC now owns 45,178 shares of the biotechnology company's stock valued at $5,476,000 after purchasing an additional 5,166 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Sarepta Therapeutics by 6.4% in the third quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 196 shares in the last quarter. Finally, DMC Group LLC raised its stake in shares of Sarepta Therapeutics by 2.9% in the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company's stock valued at $400,000 after purchasing an additional 93 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.